PMC:7600245 / 24085-24232 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T91","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"T92","span":{"begin":47,"end":56},"obj":"Disease"}],"attributes":[{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"covery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-tr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T227","span":{"begin":61,"end":63},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"}],"text":"covery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-tr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T330","span":{"begin":72,"end":83},"obj":"Chemical"},{"id":"T331","span":{"begin":134,"end":144},"obj":"Chemical"}],"attributes":[{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"}],"text":"covery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-tr"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T13","span":{"begin":47,"end":56},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"covery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-tr"}

{"project":"LitCovid-PubTator","denotations":[{"id":"643","span":{"begin":15,"end":23},"obj":"Species"},{"id":"644","span":{"begin":92,"end":100},"obj":"Species"},{"id":"655","span":{"begin":72,"end":83},"obj":"Chemical"},{"id":"656","span":{"begin":134,"end":144},"obj":"Chemical"},{"id":"665","span":{"begin":38,"end":56},"obj":"Disease"}],"attributes":[{"id":"A643","pred":"tao:has_database_id","subj":"643","obj":"Tax:9606"},{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Tax:9606"},{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"MESH:C462182"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"MESH:C086979"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"covery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-tr"}